{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The IMWG uniform response criteria define; Complete response(CR) as negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow(BM). Stringent CR as CR+normal free light chain ratio and absence of clonal cells in BM Very good partial response (PR) as serum and urine M-protein (monoclonal paraprotein) detectable by immunofixation but not on electrophoresis or 90% or \\>reduction in serum and urine M-protein level \\<100 milligram(mg) per 24 hour(hr).PR as \\<=50% reduction of serum and \\<= 90% of urine M-protein or up to \\<200 mg/24 hr.","groups":[{"description":"Bortezomib 1.3 milligram (mg) per meter\\^2 (m\\^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).","id":"OG000","title":"Bortezomib and Dexamethasone"}],"populationDescription":"The study was terminated. Due to insufficient number of participants, the outcome measure data was not analyzed.","reportingStatus":"POSTED","timeFrame":"Week 24 or Early termination visit (30-45 days after last dose)","title":"Percentage of Participants With Renal Compromised Multiple Myeloma by International Myeloma Working Group (IMWG) Uniform Response Criteria","type":"PRIMARY"}